Brief: Outlook Therapeutics Says FDA Acknowledged Receipt Of Co's BLA Resubmission - SEC Filing
08/04/2025 22:11
April 8 (Reuters) - Outlook Therapeutics Inc OTLK.O: OUTLOOK THERAPEUTICS INC - FDA ACKNOWLEDGES RECEIPT OF OUTLOOK THERAPEUTICS' BLA RESUBMISSION - SEC FILING OUTLOOK THERAPEUTICS INC - FDA SETS PDUFA GOAL DATE OF AUGUST 27, 2025 - SEC FILING OUTLOOK THERAPEUTICS - FDA DETERMINED CLASS 2 REVIEW FOR OUTLOOK THERAPEUTICS' BLA FOR ONS-5010- SEC FILING Source text: [ID:n0001558370-25-004606] Further company coverage: OTLK.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce